We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
IGC Pharma Inc | AMEX:IGC | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.573 | 0 | 12:00:01 |
India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company’s 2023 fiscal year.
The highlights for the quarter are:
Revenue was approximately $212 thousand and $77 thousand for the three months ended June 30, 2022, and June 30, 2021, respectively. Revenue in both quarters was primarily derived from our Life Sciences segment, which involved sales of products such as lotion, gummies, and alcohol-based hand sanitizers, among others.
Selling, general, and administrative (“SG&A”) expenses were approximately $1.5 million for the three months ended June 30, 2022, and approximately $1.8 million for the three months ended June 30, 2021, a decrease of approximately $226 thousand or 13% stemming mostly from a decrease in marketing and legal expenses. SG&A expenses consist primarily of employee-related expenses, sales and marketing, professional and legal fees, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any.
Research and Development (“R&D”) expenses were $1.4 million during the three months ended June 30, 2022, and approximately $444 thousand for the three-month ended June 30, 2021. The increase of approximately $950 thousand or 214% is primarily attributable to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on TGR-63. We anticipate additional increases in R&D expenses as the Phase 2 trials on IGC-AD1 commence.
Net loss for the three months ended June 30, 2022, was approximately $2.8 million or ($0.05) per share, compared to approximately $1.8 million or ($0.04) per share for the three months ended June 30, 2021.
About IGC:
IGC has two segments: Life Sciences and Infrastructure. The company is based in Maryland, U.S.A.
Forward-looking Statements: This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
< Financial Tables to Follow>
India Globalization Capital, Inc.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
(Unaudited)
June 30, 2022 ($)
March 31, 2022 ($)
ASSETS
Current assets:
Cash and cash equivalents
8,053
10,460
Accounts receivable, net
147
125
Inventory
3,622
3,548
Deposits and advances
905
978
Total current assets
12,727
15,111
Intangible assets, net
937
917
Property, plant and equipment, net
9,161
9,419
Claims and advances
922
937
Operating lease asset
419
450
Total long-term assets
11,439
11,723
Total assets
24,166
26,834
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
456
981
Accrued liabilities and others
1,200
1,457
Short-term loans
3
3
Total current liabilities
1,659
2,441
Long-term loans
143
144
Other liabilities
16
16
Operating lease liability
308
341
Total non-current liabilities
467
501
Total liabilities
2,126
2,942
Commitments and Contingencies – See Note 12
Stockholders’ equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of June 30, 2022, and March 31, 2022.
Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 51,840,603 and 51,054,017 shares issued and outstanding as of June 30, 2022 and March 31, 2022, respectively.
117,171
116,019
Accumulated other comprehensive loss
(3,187
)
(2,968
)
Accumulated deficit
(91,944
)
(89,159
)
Total stockholders’ equity
22,040
23,892
Total liabilities and stockholders’ equity
24,166
26,834
These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 5, 2022.
India Globalization Capital, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except loss per share and share data)
(Unaudited)
Three months ended June 30,
2022 ($)
2021 ($)
Revenue
212
77
Cost of revenue
(70
)
(51
)
Gross profit
142
26
Selling, general and administrative expenses
(1,550
)
(1,776
)
Research and development expenses
(1,394
)
(444
)
Operating loss
(2,802
)
(2,194
)
Impairment of investment
-
(37
)
Other income, net
17
443
Loss before income taxes
(2,785
)
(1,788
)
Income tax expense/benefit
-
-
Net loss attributable to common stockholders
(2,785
)
(1,788
)
Foreign currency translation adjustments
(219
)
(86
)
Comprehensive loss
(3,004
)
(1,874
)
Loss per share attributable to common stockholders:
Basic & diluted
$
(0.05
)
$
(0.04
)
Weighted-average number of shares used in computing loss per share amounts:
51,616,598
47,910,866
These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 05, 2022.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005223/en/
Claudia Grimaldi 301-983-0998
1 Year IGC Pharma Chart |
1 Month IGC Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions